Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Plasma cell 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hemostatic Disorders 1Hemorrhagic Disorders 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

venetoclax 26ibrutinib 23Rituximab 22Cyclophosphamide 21obinutuzumab 18acalabrutinib 18fludarabine phosphate 13fludarabine 13zanubrutinib 8Bendamustine Hydrochloride 8pirtobrutinib 7Biopsy 7Specimen Handling 6Lenalidomide 6CT-P10 6Whole-Body Irradiation 5Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4duvelisib 3Melphalan 3Chlorambucil 3Busulfan 3idelalisib 2daratumumab 2Vincristine 2Prednisone 2Patient Reported Outcome Measures 2Observation 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × ARQ531 × Clear all
NCT05624554 2026-03-16

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
300 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡